This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: October 6, 2009
Last updated: May 19, 2017
Last verified: May 2017
This is an open-label, Phase I, single-center, single-dose administration study to determine the absolute bioavailability, clearance, and volume of distribution of GDC-0449 (Part A) and to determine the routes of excretion and extent of metabolism of GDC-0449 (Part B). Parts A and B will be conducted sequentially, with ≥ 7 days between dosing the sixth subject in Part A and dosing the first subject in Part B. In each part, 6 healthy female subjects of non-childbearing potential, between 18 and 65 years of age (inclusive), will be dosed.

Condition Intervention Phase
Healthy Drug: GDC-0449 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label Absorption, Distribution, Metabolism, and Excretion (ADME) Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • PK (Max observed and time to max plasma concentrations, area under the plasma concentration-time curve, absolute bioavailability, total plasma clearance, vol of dist, plasma terminal phase half-life, cumulative % excretion in urine and feces [Part B]) [ Time Frame: Until study discontinuation ]

Secondary Outcome Measures:
  • Safety outcome measures (incidence, nature, and severity of adverse events; change in clinical laboratory results; change in vital signs; change in electrocardiogram [ECG]; and change in physical examination findings) [ Time Frame: Until study discontinuation ]

Enrollment: 24
Actual Study Start Date: September 2009
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: GDC-0449
oral dosage administration, intravenous dosage administration
Experimental: B Drug: GDC-0449
oral dosage administration


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Female
  • Non-childbearing potential
  • Body mass index (BMI) between 18 and 32 kg/m^2, inclusive
  • In good health, determined by no clinically significant findings on physical examination, medical history, 12-lead ECG, and vital signs
  • Negative test for drugs of abuse at screening (does not include alcohol) and at admission to the clinical research facility (does include alcohol)

Exclusion Criteria

  • History or clinical manifestations of clinically significant metabolic, hepatic, renal, hematologic, pulmonary, cardiovascular, endocrine, gastrointestinal (including gastric or duodenal ulcers), urologic, neurologic, inflammatory, or psychiatric disorders, or cancer
  • History of symptomatic hypotension, idiopathic orthostatic hypotension, or other autonomous-failure syndromes
  • History of severe physical injury, direct impact trauma, or neurological trauma within 6 months prior to Day -1
  • History of stomach or intestinal surgery, stomach disease, or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy are allowed)
  • History of alcoholism, drug abuse, or drug addiction (including soft drugs like cannabis products)
  • Use of any prescription medications/products, including known enzyme-inducing/inhibiting agents, over-the-counter medication, or other non-prescription preparations (including supplements, vitamins, minerals, phytotherapeutic/herbal/ plant-derived preparations, the tryptophans, and St. John's wort or other hypericum perforatum-containing substance) within 2 weeks prior to Day -1, with the exception of hormone-replacement therapy
  • Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 60 days prior to Day -1 or within 5 times the elimination half-life of the respective drug; participation in a trial involving administration of ^1^4C-radiolabeled compound(s) within 6 months prior to Day -1; participation in more than two other drug trials within 1 year prior to Day -1
  • Receipt of any vaccination or immunization within 1 month prior to Day -1
  • Use of any nicotine-containing or nicotine-replacement products within 6 months prior to Day -1
  • Consumption of alcohol or methylxanthine-containing beverages or food
  • Receipt of blood products within 2 months prior to Day -1
  • Donation of > 100 mL of blood within 60 days prior to Day -1; donation of > 1.0 litres of blood within 10 months prior to Day -1
  • Irregular defecation pattern, i.e., less than once per 2 days within 6 months prior to Day -1; acute constipation problems within 3 weeks prior to Day -1 (Part B subjects only)
  • Poor peripheral venous access
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00991718

Sponsors and Collaborators
Genentech, Inc.
Study Director: Jennifer Low, M.D. Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT00991718     History of Changes
Other Study ID Numbers: SHH4683g
Study First Received: October 6, 2009
Last Updated: May 19, 2017

Keywords provided by Genentech, Inc.:
GDC0449 processed this record on June 23, 2017